Proteomics for biomarker discovery in malignant melanoma

Expert Review of Dermatology

Volumn 3, Issue 2, 2008, Pages 209-220

  Findeisen, Peter ^a   Peccerella, Teresa ^a   Neumaier, Michael ^a   Schadendorf, Dirk ^b  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Biomarker; Malignant melanoma; Mass spectrometry; Profiling; Proteomics

Indexed keywords

ALPHA ENOLASE; BIOLOGICAL MARKER; CALCYCLIN; CATHEPSIN B; CATHEPSIN D; CENTROMERE PROTEIN F; COMPLEMENTARY DNA; ELONGATION FACTOR 1; EZRIN; GALECTIN 1; GLUCOSE REGULATED PROTEIN; HEAT SHOCK PROTEIN; HEAT SHOCK PROTEIN 90; LIM PROTEIN; LIPOCORTIN 1; MELANOMA ANTIGEN; MULTIDRUG RESISTANCE PROTEIN; NUCLEAR PROTEIN; NUCLEOPHOSMIN; NUCLEOSIDE DIPHOSPHATE KINASE A; PROTEIN DISULFIDE ISOMERASE; PROTEIN HCC 1; PROTEIN KINASE C INHIBITOR; PROTEIN MUC 18; PROTEIN SH3; RAN PROTEIN; STATHMIN; TRIOSEPHOSPHATE ISOMERASE; UNCLASSIFIED DRUG; VIMENTIN;

AQUEOUS HUMOR; CANCER DIAGNOSIS; CANCER RELAPSE; CANCER STAGING; EARLY DIAGNOSIS; HIGH THROUGHPUT SCREENING; HUMAN; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MELANOMA; MELANOMA CELL; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN PROCESSING; PROTEOMICS; REVIEW; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; TWO DIMENSIONAL GEL ELECTROPHORESIS; UVEA MELANOMA;

EID: 55249088770     PISSN: 17469872     EISSN: None     Source Type: Journal    
DOI: 10.1586/17469872.3.2.209     Document Type: Review

References (108)

1. Markovic S, Erickson L, Rao R et al. Malignant melanoma in the 21st Century, part 1: epidemiology, risk factors, screening, prevention, and diagnosis. Mayo Clin. Proc. 82(3), 364-380 (2007).
2. Brochez L, Naeyaert J. Serological markers for melanoma. Br. J. Dermatol. 143(2), 256-268 (2000).
3. Linette G, Carlson J, Slominski A, Mihm M, Ross J. Biomarkers in melanoma: stage III and IV disease. Expert Rev. Mol. Diagn. 5(1), 65-74 (2005).
4. Torabian S, Kashani-Sabet M. Biomarkers for melanoma. Curr. Opin. Oncol. 17(2), 167-171 (2005).
5. Utikal J, Schadendorf D, Ugurel S. Serologic and immunohistochemical prognostic biomarkers of cutaneous malignancies. Arch. Dermatol. Res. 298(10), 469-477 (2007).
6. Bosserhoff A. Novel biomarkers in malignant melanoma. Clin. Chim. Acta 367(1-2), 28-35 (2006).
7. Rifai N, Gillette M, Carr S. Protein biomarker discovery and validation: the long and uncertain path to clinical utility. Nat. Biotechnol. 24(8), 971-983 (2006).
8. Wulfkuhle JD, Paweletz CP, Steeg PS, Petricoin REF, Liotta L. Proteomic approaches to the diagnosis, treatment, and monitoring of cancer. Adv. Exp. Med. Biol. 532, 59-68 (2003).
9. Aebersold R, Mann M. Mass spectrometry-based proteomics. Nature 422(6928), 198-207 (2003).
10. Hortin G. The MALDI-TOF mass spectrometric view of the plasma proteome and peptidome. Clin. Chem. 52(7), 1223-1237 (2006).
11. Ahn N, Shabb J, Old W, Resing K. Achieving in-depth proteomics profiling by mass spectrometry. ACS Chem. Biol. 2(1), 39-52 (2007).
12. Tannu N, Hemby S. Two-dimensional fluorescence difference gel electrophoresis for comparative proteomics profiling. Nat. Protoc. 1(4), 1732-1742 (2006).
13. Maurya P, Meleady P, Dowling P, Clynes M. Proteomic approaches for serum biomarker discovery in cancer. Anticancer Res. 27(3A), 1247-1255 (2007).
14. Clauser K, Hall S, Smith D et al. Rapid mass spectrometric peptide sequencing and mass matching for characterization of human melanoma proteins isolated by two-dimensional PAGE. Proc. Natl Acad. Sci. USA 92(11), 5072-5076 (1995).
15. de Souza G, Godoy L, Teixeira V et al. Proteomic and SAGE profiling of murine melanoma progression indicates the reduction of proteins responsible for ROS degradation. Proteomics 6(5), 1460-1470 (2006).
16. Buscà R, Berra E, Gaggioli C et al. Hypoxia-inducible factor 1α is a new target of microphthalmia-associated transcription factor (MITF) in melanoma cells. J. Cell Biol. 170(1), 49-59 (2005).
17. Sinha P, Kohl S, Fischer J et al. Identification of novel proteins associated with the development of chemoresistance in malignant melanoma using two-dimensional electrophoresis. Electrophoresis 21(14), 3048-3057 (2000).
18. Poland J, Schadendorf D, Lage H et al. Study of therapy resistance in cancer cells with functional proteome analysis. Clin. Chem. Lab. Med. 40(3), 221-234. (2002).
19. Sinha P, Poland J, Kohl S et al. Study of the development of chemoresistance in melanoma cell lines using proteome analysis. Electrophoresis 24(14), 2396-2404 (2003).
20. Carta F, Demuro P, Zanini C et al. Analysis of candidate genes through a proteomics-based approach in primary cell lines from malignant melanomas and their metastases. Melanoma Res. 15(4), 235-244 (2005).
21. Anderson N, Polanski M, Pieper R et al. The human plasma proteome: a nonredundant list developed by combination of four separate sources. Mol. Cell Proteomics 3(4), 311-326 (2004).
22. Bernard K, Litman E, Fitzpatrick J et al. Functional proteomic analysis of melanoma progression. Cancer Res. 63(20), 6716-6725 (2003).
23. Pardo M, Garcia A, Thomas B et al. Proteome analysis of a human uveal melanoma primary cell culture by 2-DE and MS. Proteomics 5(18), 4980-4993. (2005).
24. Zuidervaart W, Hensbergen P, Wong M-C et al. Proteomic analysis of uveal melanoma reveals novel potential markers involved in tumor progression. Invest. Ophthalmol. Vis. Sci. 47(3), 786-793 (2006).
25. Pardo M, Dwek R, Zitzmann N. Proteomics in uveal melanoma research: opportunities and challenges in biomarker discovery. Expert Rev. Proteomics 4(2), 273-286 (2007).
26. Pardo M, Garcia A, Thomas B et al. The characterization of the invasion phenotype of uveal melanoma turnout cells shows the presence of MUC18 and HMG- 1 metastasis markers and leads to the identification of DJ-1 as a potential serum biomarker. Int. J. Cancer 119(5), 1014-1022 (2006).
27. Culp W, Neal R, Massey R et al. Proteomic analysis of tumor establishment axid growth in the B16-F10 mouse melanoma model. J. Proteome Res. 5(6), 1332-1343 (2006).
28. Issaq H, Veenstra T. The role of electrophoresis in disease biomarker discovery. Electrophoresis 28(12), 1980-1988 (2007).
29. Hoffman S, Won AJ, Echan L, Speicher D. Higher dimensional (Hi-D) separation strategies dramatically improve the potential for cancer biomarker detection in serum and plasma. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 849(1-2), 43-52 (2007).
30. Deutsch E, Eng J, Zhang H et al. Human Plasma Peptide Atlas. Proteomics 5(13), 3497-3500 (2005).
31. States D, Omenn G, BlackwelI T et al. Challenges in deriving high-confidence protein identifications from data gathered by a HUPO plasma proteome collaborative study. Nat. Biotechnol. 24(3), 333-338 (2006).
32. Lee H-J, Lee E-Y, Kwon M-S, Paik Y-K. Biomarker discovery from the plasma proteome using multidimensional fractionation proteomics. Curr. Opin. Chem. Biol. 10(1), 42-49 (2006).
33. Zhang Z, Bast JRC, Yu Y et al. Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer. Cancer Res. 64(16), 5882-5890 (2004).
34. Pusch W, Flocco M, Leung S-M, Thiele H, Kostrzewa M. Mass spectrometry-based clinical proteomics. Pharmacogenomia 4(4), 463-476 (2003).
35. Villanueva J, Philip J, Entenberg D et al. Serum peptide profiling by magnetic particle-assisted, automated sample processing and MALDI-TOF mass spectrometry. Anal. Chem. 76(6), 1560-1570 (2004).
36. Lopez M, Mikulskis A, Kuzdzal S et al. A novel, high-throughput workflow for discovery and identification of serum carrier protein-bound peptide biomarker candidates in ovarian cancer samples. Clin. Chem. 53(6), 1067-1074 (2007).
37. Tomecki K, Montague P, Hearing JV. Serum and urine protein differences in patients with malignant melanoma. J. Natl Cancer Inst. 64(1), 29-32 (1980).
38. Ferrari L, Seraglia. R, Rossi C et al. Protein profiles in sera of patients with malignant cutaneous melanoma. Rapid Commun. Mass Spectrom. 14(13), 1149-1154 (2000).
39. Wilson L, Tran L, Morton D, Hoon D. Detection of differentially expressed proteins in early-stage melanoma patients using SELDI-TOF mass spectrometry. Ann. NY Acad. Sci. 1022, 317-322 (2004).
40. Mian S, Ugurel S, Parkinson E et al. Serum proteomic fingerprinting discriminates between clinical stages and predicts disease progression in melanoma patients. J. clin. Oncol. 23(22), 5088-5093 (2005).
41. Matharoo-Ball B, Ratcliffe L, Lancashire L et al. Diagnostic biomarkers differentiating metastatic melanoma patients from healthy controls identified by an integrated MALDI-TOF mass spectrometry/ bioinformatic approach. Proteomics Clin. Applic. 1(6), 605-620 (2007).
42. Ragazzi F, Vogliardi S, Allegri G et al. Cluster analysis of serum proteins in malignant cutaneous melanoma: search for disease markers. Rapid Commun. Mass Spectrom. 17(13), 1511-1515 (2003).
43. Seraglia R, Vogliardi S, Allegri G et al. Search for melanoma markers in plasma and serum samples. Eur. J. Mass Spectrom. 11(3), 353-360 (2005).
44. Mischak H, Apweiler R, Banks R et al. Clinical proteomics: a need to define the field and to begin to set adequate standards. Proteomics Clin. Applic. 1(2), 148-156 (2007).
45. Deichmann M, Kahle B, Moser K, Wacker J, Wüst K. Diagnosing melanoma patients entering American Joint Committee on Cancer stage IV, C-reactive protein in serum is superior to lactate dehydrogenase. Br. J. Cancer 91(4), 699-702 (2004).
46. Koomen J, Zhao H, Li D et al. Diagnostic protein discovery using liquid chromatography/mass spectrometry for proteolytic peptide targeting. Rapid Commun. Mass Spectrom. 19(12), 1624-1636 (2005).
47. Missotten G, Beijnen J, Keunen J, Bonfrer J. Proteomics in uveal melanoma. Melanoma Res. 13(6), 627-629 (2003).
48. Kaiser T, Wittke S, Just I et al. Capillary electrophoresis coupled to mass spectrometer for automated and robust polypeptide determination in body fluids for clinical use. Electrophoresis 25(13), 2044-2055 (2004).
49. Brouard M, Saurat JH, Ghanem G, Siegenthaler G. Urinary excretion of epidermal-type fatty acid-binding protein and S100A7 protein in patients with cutaneous melanoma. Melanoma Res. 12(6), 627-631 (2002).
50. Kolch W. Neusüss C, Pelzing M, Mischak H. Capillary electrophoresis-mass spectrometry as a powerful tool in clinical diagnosis and biomarker discovery. Mass Spectrom. Rev. 24(6), 959-977 (2005).
51. Weissinger E, Wittke S, Kaiser T et al. Proteomic patterns established with capillary electrophoresis and mass spectrometry for diagnostic purposes. Kidney Int. 65(6), 2426-2434 (2004).
52. Theodorescu D, Fliser D, Wittke S et al. Pilot study of capillary electrophoresis coupled to mass spectrometry as a tool to define potential prostate cancer biomarkers in urine. Electrophoresis 26(14), 2797-2808 (2005).
53. Decramer S, Wittke S, Mischak H et al. Predicting the clinical outcome of congenital unilateral ureteropelvic junction obstruction in newborn by urinary proteome analysis. Nat. Med. 12(4), 398-400 (2006).
54. Theodorescu D, Wittke S, Ross M et al. Discovery and validation of new protein biomarkers for urothelial cancer: a prospective analysis. Lancet Oncol. 7(3), 230-240 (2006).
55. Schiffer E, Mischak H, Novak J. High resolution proteome/peptidome analysis of body fluids by capillary electrophoresis coupled with MS. Proteomics 6(20), 5615-5627 (2006).
56. Diamandis E. Point: proteomic patterns in biological fluids: do they represent the future of cancer diagnostics? Clin. Chem. 49(8), 1272-1275 (2003).
57. Garber K. Debate rages over proteomic patterns. J. Natl Cancer Inst. 96(11), 816-818 (2004).
58. Diamandis E. Serum proteomic profiling by matrix-assisted laser desorption-ionitation time-of-flight mass spectrometry for cancer diagnosis: next Steps. Cancer Res. 66(11), 5540-5541 (2006).
59. Petricoin E, Ardekani A, Hitt B et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet 359(9306), 572-577 (2002).
60. Baggerly K, Morris J, Coombes K. Reproducibility of SELDI-TOF protein patterns in serum: comparing datasets from different experiments. Bioinformatics 20(5), 777-785 (2004).
61. Check E. Proteomics and cancer: running before we can walk? Nature 429(6991), 496-497 (2004).
62. Semmes O, Cazares L, Ward M et al. Discrete serum protein signatures discriminate between human retrovirus-associated hematologic and neurologic disease. Leukemia 19(7), 1229-1238 (2005).
63. McLerran D, Grizzle WE, Feng Z et al. analytical validation of serum proteomic profiling for diagnosis of prostate cancer: sources of sample bias. Clin. Chem. 54(1), 44-52 (2008).
64. McLerran D, Grizzle WE, Feng Z et al. SELDI-TOF MS whole serum proteomic profiling with IMAC surface does not reliably-detect prostate cancer. Clin. Chem. 54(1), 53-60 (2008).
65. Banks R, Stanley A, Cairns D et al. Influences of blood sample processing on low-molecular-weight proteome identified by surface-enhanced laser desorption/ionization mass spectrometry. Clin. Chem. 51(9), 1637-1649 (2005).
66. Findeisen P, Sismanidis D, Riedl M, Costina V, Neumaier A. Preanalytical impact of sample handling on proteome profiling experiments with matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Clin. Chem. 51(12), 2409-2411 (2005).
67. Baumann S, Ceglarek U, Fiedler G et al. Standardized approach to proteome profiling of human serum based on magnetic bead separation and matrix-assisted laser desorption/ionization Time-of-flight mass spectrometry. Clin. Chem. 51(6), 973-980 (2005).
68. West-Nielsen M, Hogdall E, Marchiori E et al. Sample handling for mass spectrometric proteomic investigations of human sera. Anal Chem. 77(16), 5114-5123 (2005).
69. West-Norager M, Kelstrup C, Schou C et al. Unravelling in vitro variables of major importance for the outcome of mass spectrometry-based serum proteomics. J. Chromatogr. B 847(1), 30-37 (2007).
70. Karsan A, Eigl B, Flibotte S et al. Analytical and preanalytical biases in serum proteomic pattern analysis for breast cancer diagnosis. Clin. Chem. 51(8), 1525-7-1528 (2005).
71. Ransohoff D. Lessons from controversy: ovarian cancer screening and serum proteomics. J. Natl Cancer Inst. 97(4), 315-319 (2005).
72. Hong H, Dragan Y, Epstein J et al. Quality control and quality assessment of data from surface-enhanced laser desorption/ionization (SELDI) time-of flight (TOF) mass spectrometry (MS). BMC Bioinformatics 6 (Suppl. 2), 5 (2005).
73. Villanueva J, Philip J, Chaparro C et al. Correcting common errors in identifying cancer-specific serum peptide signatures. J. Proteome Res. 4(4), 1060-1072 (2005).
74. Hu J, Coombes K, Morris 3, Baggerty K. The importance of experimental design in proteomic mass spectrometry experiments: some cautionary tales. Brief. Funct. Genomic. Proteomic. 3(4), 322-331 (2005).
75. Taylor C, Paton N, Lilley K et al. The minimum information about a proteomics experiment (MIAPE). Nat. Biotechnol. 25(8), 887-893 (2007).
76. Brazma A, Krestyaninova M, Sarkans U. Standards for systems biology. Nat. Rev. Genet. 7(8), 593-605 (2000).
77. Anderson N, Anderson N. The human plasma proteome: history, character, and diagnostic prospects. Mol Cell. Proteomics 1(11), 845-867 (2002).
78. Koomen J, Li D, Xiao L-C et al. Direct tandem mass spectrometry reveals limitations in protein profiling experiments for plasma biomarker discovery. J. Proteome Res. 4(3), 972-981 (2005).
79. Villanueva J, Shaffer DR, Philip J et al. Differential exoprotease activities confer tumor-specific serum peptidome patterns. J. Clin. Invest. 116(1), 271-284 (2006).
80. Omenn G. Strategies for plasma proteomic profiling of cancers. Proteomics 6(20), 5662-5673 (2006).
81. Whiteaker J, Zhang H, Eng J et al. Head-to-head comparison of serum fractionation techniques. J. Proteome Res. 6(2), 828-836 (2007).
82. Diamandis E. Oncopeptidomics: a useful approach for cancer diagnosis; Clin. Chem. 53(6), 1004-1006 (2007).
83. Bossuyt P, Reitsma J, Bruns D et al. The STARD statement for reporting studies of diagnostic accuracy: explanation and elaboration. Clin. Chem. 49(1), 7-18 (2003).
84. Diamandis E. Peptidomics for cancer diagnosis: presemt and future. J. Proteome Res. 5(9), 2079-2082 (2006).
85. Lopez-Otin C, Overall C. Protease degradomics: a new challenge for proteomics. Nat. Rev. Mol. Cell Biol. 3(7), 509-519 (2002).
86. Villanueva J, Martorella A, Lawlor K et al. Serum peptidome patterns that distinguish metastatic thyroid carcinoma from cancer-free controls are unbiased by gender and age. Mol. Cell. Proteomics 5(10), 1840-1852 (2006).
87. Capon F, Emonard H, Hornebeck W, Maquart F, Bernard P. Expression and activation of pro-gelatinase A by human melanoma cell lines with different tumorigenic potential. Clin. Exp. Metastasis 17(6), 463-469 (1999).
88. Ntayi C, Labrousse A-L, Debret R et al. Elastin-derived peptides upregulate matrix metalloproteinase-2-mediated melanoma.cell invasion through elastinbinding protein. J. Invest. Dermatol. 122(2), 256-265 (2004).
89. Jessani N, Niessen S, Wei B et al. A streamlined platform for high-content functional proteomics of primary human specimens. Nat. Methods 2(9), 691-697 (2005).
90. Contacts T, Hood B, Veenstra T. Sampling and analytical strategies for biomarker discovery using mass spectrometry. Biotechniques 40(6), 799-805 (2006).
91. Findeisen P, Post S, Wenz F, Neumaier M. Addition of exogenous reporter peptides to serum sampples before mass spectrometry-based protease profiling provides advantages over profiling of endogenous peptides. Clin. Chem. 53(10), 1864-1866 (2007).
92. Villanueva J, Nazarian A, Lawlor K et al. A sequence-specific exopeptidase activity test (SSEAT) for 'functional' biomarker discovery. Mol. Cell. Proteomics 7(3), 509-518 (2008).
93. Nedelkov D, Kiernan U, Niederkofler E, Tubbs K, Nelson R. Investigating diversity in human plasma proteins. Proc. Natl Acad. Sci. USA 102(31), 10852-10857 (2005).
94. Jin M, Cataland S, Rissell M, Wu HM. A rapid test for the diagnotis of thrombotic thrombocytopenic purpura using surface enhanced laser desorption/ionization time-of-flight (SELDI-TOF)-mass spectrometry. J. Thromb. Haemost. 4(2), 333-338 (2006).
95. Mueller L, Rinner O, Schmidt A et al. SuperHirn - a novel tool for high resolution LC-MS-based peptide/protein profiling. Proteomics 7(19), 3470-3480 (2007).
96. Keshishian H, Addona T, Burgess M, Kuhn E, Carr SA. Quantitative, multiplexed assays for low abundance proteins in plasma by targeted mass spectrometry and stable isotope dilution. Mol. Cell. Proteomics 6(12), 2212-2229 (2007).
97. Anderson L, Hunter C. Quantitative mass spectrometric multiple reaction monitoring assays for major plasma proteins. Mot. Cell. Proteomics 5(4), 573-588 (2006).
98. Bondar OP, Barnidge DR, Klee EW, Davis BJ, Mee GG. LC-MS/MS quantification of Zn-α2 glycoprotein: a potential serum biomarker for prostate cancer. Clin. Chem. 53(4), 673-678 (2007).
99. Hortin GL. A new era in protein quantification in clinical laboratories: application of liquid chromatographytandem mass spectrometry. Clin. Chem. 53(4), 543-544 (2007).
100. Veenstra T. Global and targeted quantitative proteomics for biomarker discovery. J. Chromatogr. B 847(1), 3-11 (2007).
101. Stahl-Zeng J, Lange V, Ossola R et al. High sensitivity detection of plasma proteins by multiple reaction monitoring of N-glycosites. Mol. Cell. Proteomics 6(10), 1809-1817 (2007).
102. Ackermann B, Berna M. Coupling immunoaffinity techniques with MS for quantitative analysis of low-abundance protein biomarkers. Expert Rev. Proteomics 4(2), 175-186 (2007).
103. Ueda K, Karagiri T, Shimada T et al. Comparative profiling of serum glycoproteome by sequential purification of glycoproteins and 2-nitrobenzensulfenyl (NBS) stable isotope labeling: a new approach for the novel biomarker discovery for cancer. J. Proteome Res. 6(9), 3475-3483 (2007).
104. Caron M, Choquet-Kastylevsky GV, Joubert-Caron R. Cancer immunomics using autoantibody signatures for biomarker discovery. Mol. Cell. Proteomics 6(7), 1115-1122 (2007).
105. Usener D, Gerhardt A, Schadendorf D, Eichmuller S. Seroreactivity against MAGE-A and LAGE-I proteins in melanoma patients. Br. J. Dermatol. 149(2), 282-288 (2003).
106. Hartmann T, Bazhin A, Schadendorf D, Eichmüller S. SEREX identification of new Lumor antigens linked to melanoma-associated retinopathy, Int. J. Cancer 114(1), 88-93 (2005).
107. Ladewig G, Reinhold U, Thirkill C et al. Incidence of antiretinal antibodies in melanoma: screening of 77 serum samples from 51 patients with American Joint Committee on Cancer stage I-IV. Br. J. Dermatol. 152(5), 931-938 (2005).
108. Hardouin J, Lasserre J-P, Sylvius LK, Joubert-Caron R, Caron M. Cancer immunomics: from serological proteome analysis to multiple affinity protein profiling. Ann. NY Acad. Sci. 1107, 223-230 (2007).